Sweden's MedCap Q4 sales rise 25%, EBITA up 68%

MedCap AB (publ)

06/02/2026 05:38

Overview

Sweden life sciences firm's Q4 net sales rose 25% yr/yr, driven by organic growth

Adjusted EBITA for Q4 increased 68%, reflecting strong performance across business areas

Company completed acquisition of LivAssured, enhancing epilepsy product portfolio

Outlook

MedCap did not provide specific guidance for future quarters or years

Result Drivers

ORGANIC GROWTH - MedCap reported 10% organic growth in Q4, with strong performances in MedTech and Assistive Tech areas

ACQUISITIONS - Acquisitions, including LivAssured, contributed to increased net sales in Assistive Tech and Specialty Pharma

MARGIN PERFORMANCE - Strong margins in Assistive Tech and MedTech, though Specialty Pharma margins remained low

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 591 mln
Q4 EPS
SEK 4.30
Q4 Net Income
SEK 65 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the investment management & fund operators peer group is "buy"

Wall Street's median 12-month price target for MedCap AB (publ) is SEK621.50, about 25.2% above its February 5 closing price of SEK496.50

The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release: ID:nMFN4QD9PM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)